))
23: Ferryx Discusses Key Milestones
Manage episode 344400545 series 3305030
Nội dung được cung cấp bởi Deepbridge Capital Discovery Podcast and Deepbridge Capital. Tất cả nội dung podcast bao gồm các tập, đồ họa và mô tả podcast đều được Deepbridge Capital Discovery Podcast and Deepbridge Capital hoặc đối tác nền tảng podcast của họ tải lên và cung cấp trực tiếp. Nếu bạn cho rằng ai đó đang sử dụng tác phẩm có bản quyền của bạn mà không có sự cho phép của bạn, bạn có thể làm theo quy trình được nêu ở đây https://vi.player.fm/legal.
Jenny Bailey (Chief Executive Officer and Co-Founder of Ferryx) joins the Deepbridge Discovery Podcast to discuss how Ferryx came to be, her background before setting up Ferryx, the challenges she has faced and the next steps and goals for Ferryx.
About Ferryx:
Ferryx Ltd was formed in 2019 as a spin-out from the University of Bristol to take anti-inflammatory bacterial products into commercial production for the benefit of humans and animals. Their proprietary bacterial products can be developed as food supplements or prescription therapeutics and will be licensed to marketing and distribution partners for market entry.
- - -
Supporting growth-focused companies and entrepreneurs has never been more important, but it is important to understand the people and ideas behind such investment opportunities.
Join the Deepbridge Capital team each week as they discuss all things Deepbridge, speak with various investment experts within the company and discover more about the founders and CEOs’ running the portfolio companies Deepbridge invests in. Each episode contains an informal conversation to understand how these leaders and teams perform in order to achieve their goals. Investments in early-stage companies are illiquid and high risk – investors could lose all of their capital.
About Ferryx:
Ferryx Ltd was formed in 2019 as a spin-out from the University of Bristol to take anti-inflammatory bacterial products into commercial production for the benefit of humans and animals. Their proprietary bacterial products can be developed as food supplements or prescription therapeutics and will be licensed to marketing and distribution partners for market entry.
- - -
Supporting growth-focused companies and entrepreneurs has never been more important, but it is important to understand the people and ideas behind such investment opportunities.
Join the Deepbridge Capital team each week as they discuss all things Deepbridge, speak with various investment experts within the company and discover more about the founders and CEOs’ running the portfolio companies Deepbridge invests in. Each episode contains an informal conversation to understand how these leaders and teams perform in order to achieve their goals. Investments in early-stage companies are illiquid and high risk – investors could lose all of their capital.
48 tập
Chia sẻ
